We have concluded a joint research agreement with Gene Techno Science Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Masaharu Tani) to obtain an antibody that kills cancer cells, and to apply for a patent.
Contents of this agreement: Joint research agreement for acquisition of monoclonal antibodies to specific antigens expressed on the surface of cancer cells
About Gene Techno Science Co., Ltd.
GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.
Reference: Gene Techno Science Co., Ltd. IR